Pupelis G, Austrums E, Snippe K
Department of Surgery, Clinical Hospital "Gailezers", Medical Academy of Latvia, Riga, Latvia.
Zentralbl Chir. 2002 Nov;127(11):975-81. doi: 10.1055/s-2002-35761.
Selection of the optimal treatment strategy in severe acute pancreatitis (SAP) is a serious clinical challenge largely due to difficult differential diagnosis of patients with early SAP. The aim of this study is a retrospective evaluation of the first experiences in the treatment of patients with SAP and early SAP according to a new complex clinical protocol (CCP).
A total of 210 patients complied with Atlanta recommendations for SAP and were included in the retrospective study. Patients were stratified into two groups according to the diagnostic and treatment strategy. Non-protocol (NP) group comprised 154 patients who had received their treatment based on previous clinical routine and subjective decision of physicians in charge. 56 patients who were managed according to the new CCP developed for SAP comprised the CCP group. CCP included:- Early assessment of the severity of acute pancreatitis (APACHE II score, presence of SIRS and/or organ dysfunction); - Immediate ICU monitoring including routine measurement of the intraabdominal pressure; - Conservative treatment including early enteral nutrition, colloids, antibacterial prophylaxis and early continuous venovenous hemofiltration (CVVHF) when indicated; - Surgical treatment when conservative treatment was not effective (progression of the organ dysfunction) or presence of infection was evident. Hospital, ICU stays and outcomes were analysed. Statistical comparison was done by Mann-Whitney U-test and Chi-square test.
The age structure and severity of the disease were similar in both groups with mean of 51.3 (15.6) vs. 46.8 (15.2) years and 9.7 (5.1) vs. 9.8 (4.4) APACHE II points in groups NP and CCP, respectively. Male/female ratio was 2 : 1, and alcohol was the main etiologic factor in about 55 % of cases in both groups. Early SAP was diagnosed in 33 % to 46 % of patients according to the results of the SOFA scoring. The results of the conservative therapy considerably improved after implementation of the CCP treatment. Surgical intervention was done in 46-52 % of patients. MODS was the main cause of death in both groups. Remarkable decrease in early mortality (within the first week from admission) was a real advantage of CCP treatment comprising 1.8 % vs. 22.1 % in NP patients, p < 0.01. Mortality from early SAP was reduced by CCP treatment to 3.8 % compared to 33 % in NP group, p < 0.01. There was a considerable reduction in postoperative mortality with CCP treatment comprising 10.3 % vs. 32.7 % in patients who did not receive CCP treatment, p < 0.05. Overall mortality associated with CCP treatment ranged to 5 %, compared to 34 % mortality in the NP treatment group, p < 0.01. Due to the considerable number of early deaths among NP patients, there was statistically longer ICU and hospital stay in CP group with mean of 14.1 (14.1) vs. 9.6 (15.2) days and 37.9 (26.7) vs. 23.4 (21.8) days, compared to NP group, p < 0.01.
Timely recognition and complex therapy of SAP including ICU monitoring, colloids, antibacterial prophylaxis, early enteral nutrition, and CVVHF is the most effective way how to manage this category of patients. Implementation of a specialised treatment protocol considerably improves outcome and reduces the number of deaths associated with surgery and early SAP.
在重症急性胰腺炎(SAP)中选择最佳治疗策略是一项严峻的临床挑战,这主要是因为早期SAP患者的鉴别诊断困难。本研究的目的是根据一种新的综合临床方案(CCP)对治疗SAP和早期SAP患者的首批经验进行回顾性评估。
共有210例符合亚特兰大SAP推荐标准的患者纳入本回顾性研究。根据诊断和治疗策略将患者分为两组。非方案(NP)组包括154例根据以往临床常规和主管医生的主观判断接受治疗的患者。56例按照为SAP制定的新CCP进行治疗的患者组成CCP组。CCP包括:- 急性胰腺炎严重程度的早期评估(APACHE II评分、全身炎症反应综合征和/或器官功能障碍的存在);- 立即入住重症监护病房(ICU)监测,包括常规测量腹内压;- 保守治疗,包括早期肠内营养、胶体液、抗菌预防,以及在有指征时进行早期连续性静脉-静脉血液滤过(CVVHF);- 当保守治疗无效(器官功能障碍进展)或明显存在感染时进行手术治疗。分析住院时间、ICU住院时间和治疗结果。采用Mann-Whitney U检验和卡方检验进行统计学比较。
两组患者的年龄结构和疾病严重程度相似,NP组和CCP组的平均年龄分别为51.3(15.6)岁和46.8(15.2)岁,APACHE II评分分别为9.7(5.1)分和9.8(4.4)分。男女比例为2∶1,两组中约55%的病例酒精是主要病因。根据序贯器官衰竭评估(SOFA)评分结果,33%至46%的患者被诊断为早期SAP。实施CCP治疗后,保守治疗效果显著改善。46%至52%的患者接受了手术干预。多器官功能障碍综合征(MODS)是两组患者死亡的主要原因。CCP治疗的真正优势在于早期死亡率(入院后第一周内)显著降低,NP组患者为22.1%,而CCP组为1.8%,p<0.01。CCP治疗使早期SAP的死亡率降至3.8%,而NP组为33%,p<0.01。CCP治疗使术后死亡率大幅降低,未接受CCP治疗的患者术后死亡率为32.7%,而接受CCP治疗的患者为10.3%,p<0.05。与CCP治疗相关的总体死亡率为5%相比,NP治疗组的死亡率为34%,p<0.01。由于NP组患者早期死亡人数较多,CCP组的ICU和住院时间在统计学上更长,NP组平均分别为9.6(15.2)天和23.4(21.8)天,而CCP组分别为14.1(14.1)天和37.9(26.7)天,p<0.01。
对SAP进行及时识别并采用包括ICU监测、胶体液、抗菌预防、早期肠内营养和CVVHF在内的综合治疗是管理这类患者的最有效方法。实施专门的治疗方案可显著改善治疗结果,并减少与手术和早期SAP相关的死亡人数。